Duaklir Pressair Powder, Metered
NDC Package 70515-001-03

11-digit billing NDC: 70515000103

Package Information

Duaklir Pressair (aclidinium bromide and formoterol fumarate) powders is dUAKLIR PRESSAIR is a combination of aclidinium bromide (an anticholinergic) and formoterol fumarate (a LABA) indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).Limitations of Use: DUAKLIR PRESSAIR is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions (5.1, 5.4)]. This formulation utilizes a powder, metered delivery system. Marketed by Covis Pharma Us, Inc, this product is identified by NDC 70515-001 and is authorized under FDA application NDA210595.

Identification & Billing

NDC Package Code
70515-001-03
Package Description
1 POUCH in 1 CARTON / 1 INHALER in 1 POUCH / 30 POWDER, METERED in 1 INHALER
Product Code
11-Digit Billing Format
70515000103
RxNorm Crosswalk
  • RxCUI: 2205094 - aclidinium bromide 400 MCG/ACTUAT / formoterol fumarate 12 MCG/ACTUAT Dry Powder Inhaler, 60 Actuations
  • RxCUI: 2205094 - 60 ACTUAT aclidinium bromide 0.4 MG/ACTUAT / formoterol fumarate 0.012 MG/ACTUAT Dry Powder Inhaler
  • RxCUI: 2205099 - Duaklir Pressair 400/12 MCG/INHAL Dry Powder Inhaler, 60 Actuations
  • RxCUI: 2205099 - 60 ACTUAT aclidinium bromide 0.4 MG/ACTUAT / formoterol fumarate 0.012 MG/ACTUAT Dry Powder Inhaler [Duaklir]
  • RxCUI: 2205099 - Duaklir Pressair 400/12 ( aclidinium bromide 400 MCG/ formoterol fumarate 12 MCG ) per ACTUAT Dry Powder Inhaler, 60 Actuations

Clinical Specifications

Proprietary Name
Duaklir Pressair
Non-Proprietary Name
Aclidinium Bromide And Formoterol Fumarate
Substance Name
Aclidinium Bromide; Formoterol Fumarate
Dosage Form
Powder, Metered - An powder dosage form that is situated inside a container that has a mechanism to deliver a specified quantity.
Administration Route
Respiratory (inhalation) - Administration within the respiratory tract by inhaling orally or nasally for local or systemic effect.
Usage Information
DUAKLIR PRESSAIR is a combination of aclidinium bromide (an anticholinergic) and formoterol fumarate (a LABA) indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).Limitations of Use: DUAKLIR PRESSAIR is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions (5.1, 5.4)].

Regulatory & Marketing

Labeler Name
Covis Pharma Us, Inc
Product Type
Human Prescription Drug
FDA Application #
NDA210595
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
03-29-2019
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (70515-001). Click a package code to view its specific billing and regulatory data.

1 POUCH in 1 CARTON / 1 INHALER in 1 POUCH / 60 POWDER, METERED in 1 INHALER

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70515-001-03 identifies a specific commercial package of 1 pouch in 1 carton / 1 inhaler in 1 pouch / 30 powder, metered in 1 inhaler of Duaklir Pressair, a human prescription drug labeled by Covis Pharma Us, Inc. This powder, metered is formulated for respiratory (inhalation) use and contains aclidinium bromide; formoterol fumarate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Covis Pharma Us, Inc on March 29, 2019. The current certification is valid through December 31, 2026.

How is this Covis Pharma Us, Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70515000103. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
70515-001-03
11-Digit CMS (5-4-2)
70515-0001-03

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.